Trial Profile
A study of GMA 204 for the treatment of Non-small cell lung cancer.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 12 Jan 2017
Price :
$35
*
At a glance
- Drugs GMA 204 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 12 Jan 2017 New trial record
- 29 Oct 2015 According to a Gmax Biopharm media release, GMA204 clinical research application has been submiteed to Zhejiang Provincial Food and Drug Administration (CFDA)